Table 4.
Analyses of risk factors for tumor recurrence after liver transplantation in 10 patients with macrovascular invasion included in the study.
| Factors | HR (95% CI) | p |
|---|---|---|
| Male sex | 0.41 (0.03–6.62) | 0.533 |
| Age | 0.99 (0.88–1.11) | 0.872 |
| MELD | 0.90 (0.67–1.20) | 0.469 |
| HBV infection | 4.12 (0.57–29.66) | 0.160 |
| HCV infection | 0.13 (0.01–1.46) | 0.098 |
| ALD | 2.27 (0.20–25.32) | 0.504 |
| AFP model | 1.14 (0.60–2.14) | 0.694 |
| Tumor number | 1.24 (0.92–1.67) | 0.154 |
| Tumor size | 0.86 (0.41–1.79) | 0.688 |
| Alpha-fetoprotein | 0.93 (0.67–1.29) | 0.654 |
| Ca 19-9 | 0.66 (0.10–4.34) | 0.663 |
| Poor tumor differentiation | 3.74 (0.22–64.64) | 0.364 |
| Neoadjuvant treatment | 1.01 (0.10–10.29) | 0.993 |
| Total ischemic time | 5.89 (0.68–51.18) | 0.108 |
| Donor age | 0.96 (0.90–1.04) | 0.346 |
| Male donor sex | 3.14 (0.32–30.55) | 0.325 |
| Intraoperative PRBC transfusions (units) | 1.54 (0.97–2.44) | 0.066 |
| Intraoperative FFP transfusions (units) | 1.20 (0.80–1.81) | 0.374 |
Hazard ratios are for quantitative variables were given per: 1 year increase for recipient and donor age; 1 point increase for MELD; 1 increase for tumor number; 1 cm increase for tumor size; 1 loge increase for alpha-fetoprotein and Ca 19-9; 1 h increase for total ischemic time; 1 unit increase for transfusions. HR = hazard ratio; 95% CI = 95% confidence interval; MELD = model for end-stage liver disease; HBV = hepatitis B virus; HCV = hepatitis C virus; ALD = alcoholic liver disease; PRBC = packed red blood cells; FFP = fresh frozen plasma.